PMID- 30068310
OWN - NLM
STAT- MEDLINE
DCOM- 20190115
LR  - 20240329
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Aug 2
TI  - Gefitinib provides similar effectiveness and improved safety than erlotinib for 
      east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
PG  - 780
LID - 10.1186/s12885-018-4685-y [doi]
LID - 780
AB  - BACKGROUND: The first-generation epidermal growth factor receptor tyrosine kinase 
      inhibitors gefitinib and erlotinib have both been proven effective for treating 
      advanced non-small cell lung cancer (NSCLC), especially in East Asian patients. 
      We conducted this meta-analysis to compare their efficacy and safety in treating 
      advanced NSCLC in this population. METHODS: We systematically searched PubMed, 
      ScienceDirect, The Cochrane Library, Scopus, Ovid MEDLINE, Embase, Web of 
      Science, and Google Scholar for the relevant studies. Overall survival (OS), 
      progression-free survival (PFS), objective response rate (ORR), disease control 
      rate (DCR), and adverse effects (AEs) were analyzed as primary endpoints. 
      RESULTS: We identified 5829 articles, among which 31 were included in the final 
      analysis. Both gefitinib and erlotinib were effective for treating advanced 
      NSCLC, with comparable PFS (95% confidence interval [CI]: 0.97-1.10, p = 0.26), 
      OS (95% CI: 0.89-1.21, p = 0.61), ORR (95% CI: 1.00-1.18, p = 0.06), and DCR (95% 
      CI: 0.93-1.05, p = 0.68). Erlotinib induced a significantly higher rate of dose 
      reduction (95% CI: 0.13-0.65, p = 0.002) and grade 3-5 AEs (95% CI: 0.27-0.71, 
      p = 0.0008). In subgroup analysis of AEs, the erlotinib group had a significantly 
      higher rate and severity of skin rash, nausea/vomiting, diarrhea, fatigue and 
      stomatitis. CONCLUSIONS: With equal anti-tumor efficacy and fewer AEs compared 
      with erlotinib, gefitinib is more suitable for treating advanced NSCLC in East 
      Asian patients. Further large-scale, well-designed randomized controlled trials 
      are warranted to confirm our findings.
FAU - Zhang, Wenxiong
AU  - Zhang W
AD  - Department of thoracic surgery, The second affiliated hospital of Nanchang 
      University, 1 Min De Road, Nanchang, 330006, China.
FAU - Wei, Yiping
AU  - Wei Y
AUID- ORCID: 0000-0003-2962-0847
AD  - Department of thoracic surgery, The second affiliated hospital of Nanchang 
      University, 1 Min De Road, Nanchang, 330006, China. weiyiping2015@163.com.
FAU - Yu, Dongliang
AU  - Yu D
AD  - Department of thoracic surgery, The second affiliated hospital of Nanchang 
      University, 1 Min De Road, Nanchang, 330006, China.
FAU - Xu, Jianjun
AU  - Xu J
AD  - Department of thoracic surgery, The second affiliated hospital of Nanchang 
      University, 1 Min De Road, Nanchang, 330006, China.
FAU - Peng, Jinhua
AU  - Peng J
AD  - Department of thoracic surgery, The second affiliated hospital of Nanchang 
      University, 1 Min De Road, Nanchang, 330006, China.
LA  - eng
GR  - 81560345/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20180802
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antineoplastic Agents)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Asian People
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality
MH  - Erlotinib Hydrochloride/adverse effects/*therapeutic use
MH  - Gefitinib/adverse effects/*therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality
MH  - Middle Aged
MH  - Progression-Free Survival
PMC - PMC6090934
OTO - NOTNLM
OT  - East Asian populations
OT  - Erlotinib
OT  - Gefitinib
OT  - Meta-analysis
OT  - Non-small cell lung cancer
OT  - Targeted therapy
COIS- Not applicable. Not applicable. The authors declare that they have no competing 
      interests. Springer Nature remains neutral with regard to jurisdictional claims 
      in published maps and institutional affiliations.
EDAT- 2018/08/03 06:00
MHDA- 2019/01/16 06:00
PMCR- 2018/08/02
CRDT- 2018/08/03 06:00
PHST- 2018/04/17 00:00 [received]
PHST- 2018/07/22 00:00 [accepted]
PHST- 2018/08/03 06:00 [entrez]
PHST- 2018/08/03 06:00 [pubmed]
PHST- 2019/01/16 06:00 [medline]
PHST- 2018/08/02 00:00 [pmc-release]
AID - 10.1186/s12885-018-4685-y [pii]
AID - 4685 [pii]
AID - 10.1186/s12885-018-4685-y [doi]
PST - epublish
SO  - BMC Cancer. 2018 Aug 2;18(1):780. doi: 10.1186/s12885-018-4685-y.